

11109186

Attorney Docket No. 57070-8020.US00

Express Mail Label No. EV 326 984 605 US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIN RE APPLICATION OF: *Dai et al.*

APPLICATION NO.: 10/584,114

FILED: June 23, 2006

FOR: TRIPTOLIDE 5,6-DERIVATIVES AS
IMMUNOMODULATORS AND ANTICANCER
AGENTS

EXAMINER: To be Assigned

ART UNIT: 1625

CONF. NO: 3360

Information Disclosure Statement Within Three Months of Application
Filing or Before First Action – 37 C.F.R. § 1.97(b)

Mail Stop Amendment
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

1. Timing of Submission

This information disclosure is being filed within three months of the filing date of this application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever occurs last (37 C.F.R. § 1.97(b)). The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

2. Cited Information

- ☒ Copies of references 1-10 are issued patent(s) and published application(s) and are not included (see C.F.R. § 1.98(a)(2)(i)).
- ☒ Copies of references 11-19 are enclosed.

3. Effect of Information Disclosure Statement (37 C.F.R. § 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior

art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

4. Fee Payment

No fees are believed due because this Information Disclosure Statement is being filed before the mailing date of the first Office Action.


However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-2207.

5. Patent Term Adjustment (37 C.F.R. § 1.704(d))

- ☐ The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).

Respectfully submitted,
Perkins Coie LLP


Date: November 3, 2006



Brian S. Boyer
Registration No. 52,643

Correspondence Address:

Customer No. 22918
Perkins Coie LLP
P.O. Box 2168
Menlo Park, California 94026
(650) 838-4300

			COMPLETE IF KNOWN		
			Application Number	10/584,114	
			Filing Date	June 23, 2006	
			First Named Inventor	Dai et al.	
			Group Art Unit	1625	
			Confirmation No.	3360	
			Examiner Name	To be Assigned	
			Attorney Docket No.	57070-8020.US00	
Sheet	1	of	1		

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear
		NUMBER	Kind Code (if known)			
	1.	4,005,108		Kupchan <i>et al.</i>	7/87	
	2.	5,430,054		Qian <i>et al.</i>	7/95	
	3.	5,663,335	A	Qi <i>et al.</i>	9/97	
	4.	5,962,516	A	Qi <i>et al.</i>	10/99	
	5.	6,004,999	A	Jung <i>et al.</i>	12/99	
	6.	6,150,539	A	Musser	11/00	
	7.	6,620,843	B1	Fidler <i>et al.</i>	9/03	
	8.	6,943,259	B2	Dai <i>et al.</i>	9/05	
	9.	7,019,151	B2	Dai <i>et al.</i>	3/06	
	10.	7,098,348	B2	Dai <i>et al.</i>	8/06	

FOREIGN PATENT DOCUMENTS						
Examiner Initial	Cite No.	Foreign Patent or Application		Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear
		Office	NUMBER			
	11.	PCT	WO05/000291	Pharmagenesis, Inc.	1/05	
	12.	PCT	WO05/020887	Pharmagenesis, Inc.	3/05	
	13.	PCT	WO04/058770	Shanghai Institute of Materia Medica	7/04	

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.				T
	14.	Englebienne <i>et al.</i> , <i>Drug Design Reviews</i> , "The Place of Biosteric Sila Substitution in Drug Design", (2005).				
	15.	Kupchan <i>et al.</i> , <i>J. Am. Chem. Soc.</i> , 94:7194-7195 (1972)				
	16.	Leuenroth and Crews, <i>Chemistry and Biology</i> 12:1259-1268 (2005)				
	17.	Ning <i>et al.</i> , <i>Tetrahedron</i> , 59(23):4209-4213.				
	18.	Shanmuganathan <i>et al.</i> , <i>J. Med. Chem.</i> , 37:821-827 (1994).				
	19.	Vierling <i>et al.</i> , <i>Journal of Fluorine Chemistry</i> , 107:337-354 (2001).				

EXAMINER	DATE CONSIDERED
----------	-----------------